mendous strides in further consolidating our manufacturing network, expanding capacity at key sites, maximizing our API and clinical research capabilities, and optimizing our global R&D footprint. We also realized ongoing efficiencies from our Global Operational Excellence Initiative, achieving superior customer service levels while simultaneously reducing inventory and achieving a reduction in our cost of goods."
"Among our goals for 2011 and beyond, our Global Operations team will focus on expanding our manufacturing capacity at key sites (including Salt Lake City, Utah; Goa, India, and Malta), increasing the number of products we manufacture internally while simultaneously seeking to lower external costs, increasing the speed and globalizing our new product launch capabilities, in addition to maximizing all assets across the company, including our API capabilities."
2010 Anda distribution revenue is expected to be approximately $830 million, and the Company expects 2011 distribution revenue of $820 to $840 million.
2011 Financial OutlookWatson estimates total net revenue for 2011 will be approximately $4.2 billion. Total Global Generics segment revenue of between $2.8 and $3.0 billion.Total Global Brands segment revenue of between $470 and $490 million.Total Anda Distribution segment revenue of between $820 and $840 million.
Adjusted cash earnings for 2011 is expected to be between $3.85 and $4.15 per diluted share and adjusted EBITDA is expected to be between $925 million and $1.0 billion.
2012-2013 Financial OutlookWatson estimates 2012 adjusted cash earnings per share to increase 20 to 25 percent year-over-year, and in 2013, the Company estimates adjusted cash earnings per share to increase 15 to 20 percent year-over-year.
Watson's January 21, 2011 Investor Day meeting is being webcast live, and can be accessed by logging onto http:
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile2
. Watson Announces Preliminary Financial Performance for FY 20103
. Watson to Host Investor Day on January 21 in New York City4
. Watsons Generic Fentora® Receives FDA Approval5
. Watson to Present at the 29th Annual JP Morgan Healthcare Conference6
. Watson Announces Novel Oral Contraceptive Approval7
. Watson and Richter Announce Exclusive License Agreement for Esmya™8
. Watson Confirms Exalgo™ Patent Challenge9
. Watson Announces Pricing of Secondary Offering By Selling Stockholder10
. Watson Announces Commencement of Secondary Offering by Selling Stockholder11
. Watson To Present At The 2010 Credit Suisse Healthcare Conference